CR9992A - Nuevos procedimientos y formulaciones - Google Patents

Nuevos procedimientos y formulaciones

Info

Publication number
CR9992A
CR9992A CR9992A CR9992A CR9992A CR 9992 A CR9992 A CR 9992A CR 9992 A CR9992 A CR 9992A CR 9992 A CR9992 A CR 9992A CR 9992 A CR9992 A CR 9992A
Authority
CR
Costa Rica
Prior art keywords
formulations
new procedures
pyrido
difluorophenyl
pyrimidin
Prior art date
Application number
CR9992A
Other languages
English (en)
Inventor
John Robert George Appleby
Lesley Anne Humphries
Philip Blatcher
Khalil As Ad Abu
Jiric Kasparec
Ann M Diederich
Lois E Vernon
John J Taggart
Richard S Lloyd
Paul G Spoors
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38049392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR9992A publication Critical patent/CR9992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición farmacéutica en forma de un comprimido administrable por vía oral que comprende una sal soluble en agua de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido [2,3-d]pirimidin-7(8H)-ona.
CR9992A 2005-11-15 2008-05-20 Nuevos procedimientos y formulaciones CR9992A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73667905P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
CR9992A true CR9992A (es) 2008-07-29

Family

ID=38049392

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9992A CR9992A (es) 2005-11-15 2008-05-20 Nuevos procedimientos y formulaciones

Country Status (18)

Country Link
US (1) US20080268044A1 (es)
EP (1) EP1954282A4 (es)
JP (1) JP2009516000A (es)
KR (1) KR20080074178A (es)
CN (3) CN102030748A (es)
AR (1) AR056218A1 (es)
AU (1) AU2006315162A1 (es)
BR (1) BRPI0618581A2 (es)
CA (1) CA2629912A1 (es)
CR (1) CR9992A (es)
EA (1) EA200801327A1 (es)
IL (1) IL191482A0 (es)
MA (1) MA29949B1 (es)
NO (1) NO20082541L (es)
PE (3) PE20100742A1 (es)
TW (1) TW200738243A (es)
WO (1) WO2007059500A2 (es)
ZA (1) ZA200803987B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
JP2009542818A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
SI2068889T1 (sl) 2006-08-10 2020-03-31 Roy C. Levitt Anakinra za uporabo pri zdravljenju sindroma bronchiolitisa obliteransa
CN102548543B (zh) * 2009-09-23 2014-02-12 韩国联合制药株式会社 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂
US20120225105A1 (en) * 2010-10-01 2012-09-06 James Swanzy Sugar-based dispersion
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1161942A3 (en) * 1998-01-30 2003-12-10 R-Tech Ueno, Ltd. Ophthalmic composition
CN100525768C (zh) * 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
CA2431904A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
BR0212822A (pt) * 2001-09-25 2005-08-30 Pharmacia Corp Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas

Also Published As

Publication number Publication date
CN101360497A (zh) 2009-02-04
EP1954282A2 (en) 2008-08-13
CA2629912A1 (en) 2007-05-24
ZA200803987B (en) 2009-12-30
CN102030748A (zh) 2011-04-27
AR056218A1 (es) 2007-09-26
AU2006315162A1 (en) 2007-05-24
KR20080074178A (ko) 2008-08-12
JP2009516000A (ja) 2009-04-16
PE20100742A1 (es) 2010-11-25
PE20070823A1 (es) 2007-08-09
IL191482A0 (en) 2009-02-11
TW200738243A (en) 2007-10-16
EP1954282A4 (en) 2011-10-12
MA29949B1 (fr) 2008-11-03
WO2007059500A3 (en) 2007-11-22
US20080268044A1 (en) 2008-10-30
PE20100743A1 (es) 2010-11-25
WO2007059500A2 (en) 2007-05-24
EA200801327A1 (ru) 2009-02-27
NO20082541L (no) 2008-08-14
BRPI0618581A2 (pt) 2011-09-06
CN102030749A (zh) 2011-04-27

Similar Documents

Publication Publication Date Title
CR9992A (es) Nuevos procedimientos y formulaciones
EP2220093A4 (en) METHOD FOR THE PRODUCTION OF SITAGLIPTIN AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
SI2056832T1 (sl) Sestavki, primerni za oralno administracijo, ki vsebujejo derivat triazolo(4,5-D) pirimidina
CU24064B1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
SI1509521T1 (sl) 1H-imidazo(4,5-C)kinolinski derivati za zdravljenje od protein kinaze odvisnih bolezni
IL186435A0 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
BRPI0519302A2 (pt) etanossulfonato de sais de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin o e metanossulfonato de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin a, composiÇÕes contendo os mesmos, processos de preparaÇço e uso
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
CU23915B1 (es) Granulación en húmedo utilizando un agente secuestrante de agua
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
TW200730531A (en) 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amine
EP1592409A4 (en) USE OF EDIBLE ACIDITY IN QUICKLY DISPERSIBLE PHARMACEUTICAL SOLID DOSAGE FORMS
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
UY28457A1 (es) Nueva composición
GB2398005B (en) Orally administrable pharmaceutical formulation
IL170518A (en) Liquid oral dosage formulations comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino) phenylacetic acid, methods for preparing them and use thereof for the manufacture of medicaments
ITMI20032523A1 (it) Forma di dosaggio per uso orale comprendente un farmaco
AR032519A1 (es) Compuestos
AR032520A1 (es) Compuestos
AR046956A1 (es) Formas cristalinas de la sal mesilato de 2,3- dimetil-8-(2,6-dimetilbencilamino)-n-hidroxietil-imidazo(1,2-a)piridin-6-carboxamida
ITMI20052342A1 (it) Formulazioni per l'igiene orale in forma di capsule

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)